Score Overview
Explore the 2021 public Archive ranking →
Where TherapeuticsMD Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- TXMD
2011: 90.5% · 2021: 91.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 2.03 | — |
1 Year2025-09-30 | $ 1.08 | 87.96% |
5 Years2021-09-30 | $ 37.00 | -94.51% |
10 Years2016-09-30 | $ 340.50 | -99.40% |
20 Years2006-06-13 | $ 1.49 | 35.88% |
All Time2003-12-11 | $ 1.25 | 63.05% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-06-13 | All Time2003-12-11 |
|---|---|---|---|---|---|---|
| Price | $ 2.03 | $ 1.08 | $ 37.00 | $ 340.50 | $ 1.49 | $ 1.25 |
| Return | — | 87.96% | -94.51% | -99.40% | 35.88% | 63.05% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3M | -$ 217K | $ 9M |
| 2025 | $ 3M | -$ 569K | $ 7M |
| 2024 | $ 1M | -$ 2M | $ 5M |
| 2023 | $ 1M | -$ 10M | $ 4M |
| 2022 | $ 69M | $ 111M | $ 38M |
| 2021 | $ 2M | -$ 172M | $ 64M |
| 2020 | $ 64M | -$ 183M | $ 80M |
| 2019 | $ 49M | -$ 176M | $ 160M |
| 2018 | $ 16M | -$ 132M | $ 161M |
| 2017 | $ 16M | -$ 76M | $ 127M |
| 2016 | $ 19M | -$ 89M | $ 131M |
| 2015 | $ 20M | -$ 85M | $ 64M |
| 2014 | $ 15M | -$ 54M | $ 51M |
| 2013 | $ 8M | -$ 28M | $ 54M |
| 2012 | $ 3M | -$ 35M | $ 1M |
| 2011 | $ 2M | -$ 12M | $ 126.42K |
| 2010 | $ 1M | -$ 2M | $ 1.5K |
| 2009 | -$ 1M | $ 42.07K | |
| 2008 | -$ 395.55K | $ 54.42K | |
| 2007 | $ 170.54K | $ 408.63K | |
| 2006 | $ 1M | $ 136.03K | $ 985.73K |
| 2005 | $ 968.09K | $ 323.45K | $ 902.26K |
| 2004 | $ 621.93K | $ 142.12K | $ 257.67K |
| IPO2003 | $ 437.59K | $ 94.11K | $ 280.39K |
TherapeuticsMD Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 64M to $ 3M and net income went from -$ 183M to -$ 569K. Revenue increased in 4 of those 5 years; net income in 4.
Between 2015 and 2025, revenue declined from $ 20M to $ 3M and net income went from -$ 85M to -$ 569K. Revenue increased in 6 of those 10 years; net income in 6.
TherapeuticsMD Inc currently holds a 20-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.
Membership
Continue TXMD’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
